Atlas Trials

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

Clinical trial NCT05269004 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05269004
Sponsor
Hoffmann-La Roche
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Multiple Sclerosis
Start date
2022-05-03
Primary completion
2027-12-31
Enrollment
1300

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.